Why Are Avalo Therapeutics Shares Plummeting On Monday
Portfolio Pulse from Vandana Singh
Avalo Therapeutics' shares plummeted by 80% in premarket trading after the Phase 2 PEAK trial of AVTX-002 for non-eosinophilic asthma failed to meet its primary endpoint. However, a positive trend was observed in a subpopulation of patients with high baseline LIGHT levels.
June 26, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics' stock price dropped by 80% after the Phase 2 PEAK trial of AVTX-002 failed to meet its primary endpoint, but a positive trend was observed in a subpopulation of patients.
The failure of the Phase 2 PEAK trial to meet its primary endpoint has led to a significant drop in Avalo Therapeutics' stock price. However, the positive trend observed in a subpopulation of patients with high baseline LIGHT levels may provide a potential novel biomarker for treatment in patients with severe non-eosinophilic asthma, which could impact the stock price in the future.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100